Portal de Periódicos da CAPES

Kill ‘Em All: Efgartigimod Immunotherapy for Autoimmune Diseases

2018; Elsevier BV; Volume: 39; Issue: 11 Linguagem: Inglês

10.1016/j.tips.2018.08.004

1873-3735

Jagadeesh Bayry, Srini V. Kaveri,

Glycosylation and Glycoproteins Research

Neonatal Fc receptors (FcRns) recycle IgGs by preventing their lysosome degradation. As this process also enhances half-life of pathogenic auto-IgG, inspired from the mechanisms of intravenous immunoglobulin, several inhibitors of IgG-FcRn interface have been conceived for treating autoimmune diseases. Among them, the high-affinity FcRn-binding engineered Fc molecule efgartigimod has recently completed phase I clinical trial.